questionText: To ask the Secretary of State for Health and Social Care, what guidance his Department gives to medical practitioners on the (a) risks of harmful long-term effects resulting from the prescription of Lariam (Mefloquine) as an anti-malarial prophylaxis and (b) treatment recommended for alleviation of such effects when experienced by people after being prescribed Lariam.
answerText: Mefloquine, commercially known as Lariam, is effective in the prevention and treatment of malaria and is licensed for use by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. The current product information for mefloqui...
heading: Mefloquine: Side Effects